A long-term, multicenter, open-label safety study with oral 20 or 40 mg/d doses of KW-6002 (istradefylline) as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy

Trial Profile

A long-term, multicenter, open-label safety study with oral 20 or 40 mg/d doses of KW-6002 (istradefylline) as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 13 Oct 2012 Planned number of patients changed from 1100 to 1175.
    • 02 Aug 2011 New source identified and integrated (European Clinical Trials Database).
    • 16 Mar 2010 Additional lead trial investigator (Dalvi C) added as reported by ClinicalTrials.gov (NCT00203957).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top